Financial News Feed

ADMA Biologics, Inc.'s (NASDAQ:ADMA): ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company…

Read more

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be…

Read more

ADMA Bio closes $52M capital raise
08:27pm, Tuesday, 21'st May 2019

Read more

RAMSEY, N.J. and BOCA RATON, Fla., April 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA ) ("ADMA" or the "Company"), today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection. The patent claims encompass methods of preparing immune globulin via harvesting plasma from S. pneumonia vaccinated, healthy adult human donors and pooling the harvested plasma as the source for manufacturing a hyperimmune anti- pneumococcal immune globulin containing elevated opsonic antibodies to a plurality of S. pneumonia serotypes. The issued claims also encompass hyperimmune anti- pneumococcal immune globulin so prepared, methods of treating S. pneumonia infection and methods of providing immunotherapy using the hyperimmune anti- pneumococcal immune globulin. This patent will enable ADMA to protect its proprietary rights and at the same time attract collaborators interested in the development, marketing and commercialization of a much needed therapeutic for the treatment and prevention of infection in immune compromised, immunodeficient, and elderly patients who are poorly responsive to available S. pneumonia vaccines.

Read more

ADMA Biologics Inc (NASDAQ: ADMA) is making a run for the top in the market this morning, and for good reason. The company announced that it has received an FDA approval, meaning that it can now ma…

Read more

Pura Vida Investments Llc decreased its stake in Adma Biologics Inc (ADMA) by 93.49% based on its latest 2018Q4 regulatory filing with the SEC. Pura Vida Investments Llc sold 534,147 shares as the com

Read more

Proudly made at

ROCKIT